SUTRO BIOPHARMA, INC. (STRO)

Sentiment-Signal

28,9

Bearisch

Composite Score (0–100)

Insider (25%)

Keine Insider-Käufe

Institutionell (22,5%)

Keine neuen Positionen

Aktivist (12,5%)

Kein 13D/13G

Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)

Score-Verlauf (90 Tage)

Stammdaten

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Unternehmen & Branche

Name	SUTRO BIOPHARMA, INC.
Ticker	STRO
CIK	0001382101
Boerse	US
Sektor	Healthcare
Industrie	Biotechnology
SIC	2836 · Biological Products, (No Diagnostic Substances)

Wertpapier & Kennzahlen

CUSIP	–
ISIN	–
Typ	Common Stock
Marktkapitalisierung	295,2 Mio. USD
Beta	1,31
Dividendenrendite	0,00 %

Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »

Finanzkennzahlen (SEC XBRL)

Periode	Filing	Umsatz	Nettoergebnis	EPS	Aktiva	Eigenkapital
2025-12-31	10-K	102,484,000	-191,086,000	-22.49	173,830,000	-132,452,000
2025-09-30	10-Q	9,693,000	-56,857,000	-0.67	209,658,000	-87,268,000
2025-06-30	10-Q	63,745,000	-11,499,000	-0.14	262,355,000	-32,111,000
2025-03-31	10-Q	17,399,000	-75,968,000	-0.91	321,430,000	-25,811,000
2024-12-31	10-K	62,043,000	-227,461,000	-29.40	387,207,000	44,601,000
2024-09-30	10-Q	8,520,000	-48,787,000	-0.59	451,832,000	111,220,000
2024-06-30	10-Q	25,706,000	-48,018,000	-0.59	489,043,000	152,176,000
2024-03-31	10-Q	13,008,000	-58,213,000	-0.59	403,402,000	98,024,000
2023-12-31	10-K	153,731,000	-106,793,000	-1.78	470,736,000	149,649,000
2023-09-30	10-Q	16,924,000	-49,284,000	-0.81	431,734,000	112,432,000
2023-06-30	10-Q	10,412,000	-38,524,000	-0.64	464,899,000	154,715,000
2023-03-31	10-Q	12,674,000	-50,050,000	-0.85	358,016,000	185,413,000
2022-12-31	10-K	67,772,000	-119,204,000	-2.35	406,944,000	217,048,000
2022-09-30	10-Q	25,147,000	-19,488,000	-0.37	400,700,000	229,726,000
2022-06-30	10-Q	28,096,000	-26,012,000	-0.55	385,620,000	209,058,000
2022-03-31	10-Q	5,897,000	-39,110,000	-0.84	303,675,000	220,372,000
2021-12-31	10-K	61,880,000	-105,538,000	-2.29	341,408,000	252,564,000
2021-09-30	10-Q	8,517,000	-30,902,000	-0.67	371,472,000	283,580,000
2021-06-30	10-Q	28,049,000	-6,152,000	-0.13	359,788,000	307,500,000
2021-03-31	10-Q	14,660,000	-30,359,000		358,528,000	307,338,000

Fondsaktivität (Vorquartalsvergleich)

Keine Fondsdaten für dieses Unternehmen vorhanden.

Insider-Transaktionen (12 Monate)

Datum	Insider	Rolle	Typ	Stückzahl	Kurs	Wert (USD)	Δ
2025-10-15	Gerber Hans-Peter	Officer, CHIEF SCIENTIFIC OFFICER	Open Market Purchase	17,000	0.80	13,606.80	+76,0%
2025-10-15	Chow Gregory K.	Officer, CFO	Open Market Purchase	19,750	0.81	15,997.50	+89,3%
2025-10-15	Chung Jane	Director, Officer, Chief Executive Officer	Open Market Purchase	12,500	0.80	10,011.25	+55,9%
2025-10-15	Pauling David	Officer, Chief Admin. Ofcr. & GC	Open Market Purchase	12,504	0.80	9,993.20	+55,8%
2025-10-15	MATSUI CONNIE	Director	Open Market Purchase	50,000	0.80	39,950.00	+223,0%

Top-Fondshalter

Keine Fondsdaten zu dieser Aktie vorhanden.